Scholarlink

<p>The <i>PTEN</i> tumor suppressor regulates the <i>PIK3CA/AKT1</i> pathway, and its inactivation significantly contributes to tumorigenesis and progression in hormone receptor-positive/HER2-negative (HR + /HER2 −) metastatic breast cancer (MBC). In ~ 5% of these patients, PTEN loss,&#xa0;primarily due to gene deletions,&#xa0;leads to aberrant PI3K signaling and enhanced oncogenic potential. Findings from the CAPItello-291 study further establish <i>PTEN</i> together with <i>PIK3CA</i> and <i>AKT1</i> as a predictive biomarker for Capivasertib, a pan-AKT inhibitor, in these patients. Despite next-generation sequencing (NGS) being the most precise method for detecting gene losses, immunohistochemistry (IHC) offers some advantages, including accessibility, cost-effectiveness, and applicability when archival tissue is inadequate for NGS or when pre-analytical failure occurs. Notably, recent evidence supports a pragmatic IHC positivity criterion, defining PTEN deficiency as staining in less than 10% of tumor cells, regardless of intensity. In this manuscript, we provide a comprehensive overview of the clinical scenarios associated with PTEN IHC testing in HR + /HER2 − MBC, outline best practices to minimize the impact of pre-analytical and analytical variability, and propose a structured pathology report to standardize PTEN IHC evaluation in this context.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunohistochemistry for PTEN testing in HR +/HER2˗ metastatic breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月11日

查看全文
  • Nicola Fusco,
  • Elena Guerini-Rocco,
  • Isabella Castellano,
  • Umberto Malapelle

摘要

The PTEN tumor suppressor regulates the PIK3CA/AKT1 pathway, and its inactivation significantly contributes to tumorigenesis and progression in hormone receptor-positive/HER2-negative (HR + /HER2 −) metastatic breast cancer (MBC). In ~ 5% of these patients, PTEN loss, primarily due to gene deletions, leads to aberrant PI3K signaling and enhanced oncogenic potential. Findings from the CAPItello-291 study further establish PTEN together with PIK3CA and AKT1 as a predictive biomarker for Capivasertib, a pan-AKT inhibitor, in these patients. Despite next-generation sequencing (NGS) being the most precise method for detecting gene losses, immunohistochemistry (IHC) offers some advantages, including accessibility, cost-effectiveness, and applicability when archival tissue is inadequate for NGS or when pre-analytical failure occurs. Notably, recent evidence supports a pragmatic IHC positivity criterion, defining PTEN deficiency as staining in less than 10% of tumor cells, regardless of intensity. In this manuscript, we provide a comprehensive overview of the clinical scenarios associated with PTEN IHC testing in HR + /HER2 − MBC, outline best practices to minimize the impact of pre-analytical and analytical variability, and propose a structured pathology report to standardize PTEN IHC evaluation in this context.